Telitacicept for children with IgA blood vessel kidney disease
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called telitacicept for children with a kidney condition called IgA vasculitis nephritis. The medicine aims to reduce kidney damage by calming the immune system. Participation may help your child's kidneys stay healthier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 and 17 years old.
- A doctor must have confirmed the diagnosis of IgA vasculitis nephritis (a kidney inflammation often triggered by an infection).
- Urine tests must show high protein levels (protein/creatinine ratio of 1 mg/mg or higher).
- Kidney function must be reasonably good (eGFR of at least 60 mL/min/1.73 m²).
- No serious active infections (like tuberculosis, hepatitis B or C, HIV, or severe fungal infections).
- No other kidney diseases, severe osteoporosis, or other major health conditions (like heart, liver, or blood disorders).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called telitacicept for children with IgA nephropathy or IgA vasculitis nephritis, two kidney diseases that cause protein in the urine. The goal is to see if the medicine can reduce protein loss and help protect the kidneys.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests a new drug called telitacicept in people with primary membranous nephropathy, a kidney condition that causes protein leakage in urine. It aims to see if the drug can reduce protein loss and protect kidney function, potentially slowing the disease's progression.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Hear when a new IgAVN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.